Helén Tuvesson
Active Biotech is back, with one last bid for the failed MS drug Teva discarded
Laquinimod was the drug that was going to save Teva.
Over 14 years, the Israeli pharma started the compound on at least 15 clinical trials …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
